Serum levels of growth arrest specific protein 6 are increased in preeclampsia

Regulatory Peptides

Volumn 182, Issue 1, 2013, Pages 7-11

  Stepan, Holger ^a   Richter, Judit ^a,b   Kley, Karoline ^a   Kralisch, Susan ^a,b   Jank, Alexander ^a   Schaarschmidt, Wiebke ^a   Ebert, Thomas ^a   Lössner, Ulrike ^a,b   Jessnitzer, Beate ^a   Kratzsch, Jürgen ^a   Blüher, Matthias ^a   Stumvoll, Michael ^a   Fasshauer, Mathias ^a,b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Gas6; Insulin resistance; Obesity; Preeclampsia

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CREATININE; FATTY ACID; GROWTH ARREST SPECIFIC PROTEIN 6; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; BIRTH WEIGHT; BLOOD PRESSURE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GESTATIONAL AGE; GLOMERULUS FILTRATION RATE; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY FUNCTION; LIPID METABOLISM; MAJOR CLINICAL STUDY; PREECLAMPSIA; PREGNANT WOMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; UPREGULATION;

EID: 84873979791     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2012.12.013     Document Type: Article

References (24)

1. Steegers E.A., von Dadelszen P., Duvekot J.J., Pijnenborg R. Pre-eclampsia. Lancet 2010, 376:631-644.
2. Stepan H., Geide A., Faber R. Soluble fms-like tyrosine kinase 1. N Engl J Med 2004, 351:2241-2242.
3. Stepan H., Walther T. Questionable role of the angiotensin II receptor subtype 1 autoantibody in the pathogenesis of preeclampsia. Hypertension 2007, 50:e3.
4. Stepan H., Faber R. Elevated sFlt1 level and preeclampsia with parvovirus-induced hydrops. N Engl J Med 2006, 354:1857-1858.
5. Stepan H., Unversucht A., Wessel N., Faber R. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007, 49:818-824.
6. Molvarec A., Szarka A., Walentin S., Szucs E., Nagy B., Rigó J. Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia. Hypertens Res 2010, 33:892-898.
7. Poston L. Leptin and preeclampsia. Semin Reprod Med 2002, 20:131-138.
8. Miehle K., Stepan H., Fasshauer M. Leptin, adiponectin and other adipokines in gestational diabetes mellitus and pre-eclampsia. Clin Endocrinol 2012, 76:2-11.
9. Gallicchio M., Mitola S., Valdembri D., Fantozzi R., Varnum B., Avanzi G.C., et al. Inhibition of vascular endothelial growth factor receptor 2-mediated endothelial cell activation by Axl tyrosine kinase receptor. Blood 2005, 105:1970-1976.
10. Lutgens E., Tjwa M., Garcia de Frutos P., Wijnands E., Beckers L., Dahlbäck B., et al. Genetic loss of Gas6 induces plaque stability in experimental atherosclerosis. J Pathol 2008, 216:55-63.
11. Lijnen H.R., Christiaens V., Scroyen L. Growth arrest-specific protein 6 receptor antagonism impairs adipocyte differentiation and adipose tissue development in mice. J Pharmacol Exp Ther 2011, 337:457-464.
12. Report of the National High Blood Pressure Education Program working group on high blood pressure in pregnancy. Am J Obstet Gynecol 2000, 183:S1-S22.
13. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
14. Levey A.S., Stevens L.A., Schmid C.H., Zhang Lucy Y., Castro A.F., Feldman H.I., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150:604-612.
15. Sunanda G.V., Johanson R. Pre-eclampsia, diagnosis and treatment. Expert Opin Pharmacother 2001, 2:1817-1824.
16. Walker J.J. Pre-eclampsia. Lancet 2000, 356:1260-1265.
17. Bellamy L., Casas J.-P., Hingorani A.D., Williams D.J. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. Br Med J 2007, 335:974.
18. Lee I.J., Hilliard B., Swami A., Madara J.C., Rao S., Patel T., et al. Growth arrest-specific gene 6 (Gas6) levels are elevated in patients with chronic renal failure. Nephrol Dial Transplant 2012, 27:4166-4172.
19. Nagai K., Arai H., Yanagita M., Matsubara T., Kanamori H., Nakano T., et al. Growth arrest-specific gene 6 is involved in glomerular hypertrophy in the early stage of diabetic nephropathy. J Bio Chem 2003, 278:18229-18234.
20. Fourcot A., Couchie D., Chobert M.-N., Zafrani E.-S., Mavier P., Laperche Y., et al. Gas6 deficiency prevents liver inflammation, steatohepatitis, and fibrosis in mice. Am J Physiol Gastrointest Liver Physiol 2011, 300:G1043-G1053.
21. Borgel D., Clauser S., Bornstain C., Bièche I., Bissery A., Remones V., et al. Elevated growth-arrest-specific protein 6 plasma levels in patients with severe sepsis. Crit Care Med 2006, 34:219-222.
22. Ekman C., Linder A., Akesson P., Dahlbäck B. Plasma concentrations of Gas6 (growth arrest specific protein 6) and its soluble tyrosine kinase receptor sAxl in sepsis and systemic inflammatory response syndromes. Crit Care 2010, 14:R158.
23. Ekman C., Jönsen A., Sturfelt G., Bengtsson A.A., Dahlbäck B. Plasma concentrations of Gas6 and sAxl correlate with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 2011, 50:1064-1069.
24. Shugart E.C., Levenson A.S., Constance C.M., Umek R.M. Differential expression of gas and gadd genes at distinct growth arrest points during adipocyte development. Cell Growth Differ 1995, 6:1541.